LL-37 Truncated Variants (KR-12 / KS-30) for Recovery
Shorter active fragments of LL-37 (KR-12, KS-30) with retained antimicrobial activity but lower toxicity.
Why LL-37 Truncated Variants (KR-12 / KS-30) for recovery?
KR-12 (residues 18-29 of LL-37) is the smallest active fragment retaining antimicrobial activity, identified by Wang et al. (2008). KS-30 and other truncations balance efficacy with reduced cytotoxicity vs full-length LL-37. Investigated for chronic-wound, biofilm, and dental indications; no approved human indication yet.
Recovery context: Accelerating soft-tissue, tendon, gut, and post-training repair. LL-37 Truncated Variants (KR-12 / KS-30) fits this goal because its category (Recovery) and benefit profile align with the underlying mechanism.
Benefits relevant to recovery
- Wound healing research
Reference dosing by bodyweight
Anchored to the most-cited research dose (250 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 156–211 mcg |
| 60–75 kg / 132–165 lb | 191–259 mcg |
| 75–90 kg / 165–198 lb | 234–316 mcg |
| 90–105 kg / 198–231 lb | 276–374 mcg |
| >105 kg / >231 lb | 319–431 mcg |
Side effects to weigh against recovery benefit
- Localized irritation (topical)
- Limited human trial data
Also researched for
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.